HBW Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Beauty Business Agility Is Key With Few Segments Growing During Virus Shutdown

Executive Summary

Market researcher The NPD Group identifies the few prestige beauty categories that posted sales growth in the US for the week ending 28 March. Companies that can pivot or ramp up activities in winning segments – and reach consumers digitally while they shelter at home – may fare best during the coronavirus pandemic.

You may also be interested in...



L’Oreal Optimistic About Post-Shutdown Growth, Notes Likely Thinning Of Beauty Field

“It's unfortunate, but it's the Darwinian side of this industry,” L’Oreal CEO Jean-Paul Agon said on 16 April while discussing newer players’ prospects for survival through the COVID-19 crisis and L’Oreal’s own first-quarter results – down 4.8% like-for-like, but ahead of the market.

'A Black Swan Event’: Perspectives On COVID-19 Pressures On Beauty, Personal Care And Beyond

Cosmetics and personal-care manufacturers are certainly not alone in facing unprecedented challenges during the COVID-19 pandemic. Manufacturers today are uniquely vulnerable to supply chain breakdowns, and the current crisis is a perfect storm for impacts to come and already here.

Cosmetics Reform To Catch Ride On Next Coronavirus Relief Bill?

No one is saying that it will, but the Independent Cosmetic Manufacturers and Distributors is concerned that it might. The trade group is surveying its members and wider industry on COVID-19 challenges and future prospects in order to represent their interests in Washington and dissuade “uninformed cosmetics legislation.”

Related Content

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

RS149901

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel